Atazanavir

Drug Profile

Atazanavir

Alternative Names: Atazanavir sulfate; Atazor; BMS-232632-05; CGP 73547; Reyataz; TAZ

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Bristol-Myers Squibb; Emcure Pharmaceuticals; Gilead Sciences
  • Class Antiretrovirals; Oligopeptides; Pyridines; Small molecules
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 01 Feb 2016 Bristol-Myers Squibb completes an extended-access study for HIV-1 infections (NCT01003990)
  • 30 Nov 2015 Phase-III clinical trials in HIV-1 infections (Combination therapy, Treatment-experienced) in USA (PO) (NCT02603107)
  • 04 Aug 2015 Bristol-Myers Squibb completes enrolment in the phase III PRINCE2 trial for HIV-1 Infections (In children, In infants) in USA, Argentina, Brazil, Chile, Mexico, South Africa, United Kingdom, Poland, Romania, Spain and Russia (NCT01335698)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top